Wells Fargo & Company Lantern Pharma Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LTRN
# of Institutions
40Shares Held
1.27MCall Options Held
42.8KPut Options Held
5.6K-
Vanguard Group Inc Valley Forge, PA364KShares$1.17 Million0.0% of portfolio
-
New Edge Advisors, LLC New Orleans, LA157KShares$507,5100.01% of portfolio
-
Geode Capital Management, LLC Boston, MA86.3KShares$278,9000.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny81.8KShares$264,2140.0% of portfolio
-
Cm Management, LLC80KShares$258,4000.35% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $35M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...